eftilagimod alpha,pembrolizumab
immutep,merck
['tacti-002', 'lcsm,(-blcsm)', 'sclc', 'nsclc', 'eftilagimod']
tacti-002: a phase-2 study of pembro+ eftilagimod (lag-3 inhib) for mnsclc unselected pd-l1 (n=114) --&gt; orr 36.8% irecist orr 42.7% dcr 73.7% mdor nr ; mpfs 6.9 mo. 28.1% orr in pd-l1 neg tumor #asco22 #lcsm we're proud to be part of that in 
MD. Medical Oncologist Thoracic Oncol Unit Parc Taulí Hospital Univ @parctauli @UABBarcelona Researcher @i3ptT @GECP_org Fighting Lung Cancer.